Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE R REISS

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1619927969
CMS profile
208887
Location
GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$12,665.72

64 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $7,680.00 5
Travel and Lodging $2,618.52 6
Food and Beverage $2,367.20 53

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
W. L. Gore & Associates, Inc. $5,979.33 9
Glaukos Corporation $5,927.45 28
ABBVIE INC. $282.14 9
Alcon Vision LLC $144.33 4
Dompe US, Inc. $95.30 1
NEW WORLD MEDICAL,INC. $73.20 4
Bausch & Lomb Americas Inc. $71.12 4
Carl Zeiss Meditec USA, Inc. $50.25 3
Nova Eye, Inc. $22.59 1
RxSight Inc $20.01 1

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE R REISS

NPI 1619927969 · CMS profile ID 208887

Allopathic & Osteopathic Physicians / Ophthalmology

GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619927969?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE R REISS, NPI 1619927969, CMS profile ID 208887. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619927969?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GEORGE R REISS, NPI 1619927969, CMS profile ID 208887. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619927969?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GEORGE R REISS, NPI 1619927969, CMS profile ID 208887, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619927969?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

64 matching records · $12,665.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 64 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–64 of 64.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
NEW WORLD MEDICAL,INC. $22.4303/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251339083 CMS
ABBVIE INC. $12.8103/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203826286 CMS
Alcon Vision LLC $15.2203/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207471680 CMS
Alcon Vision LLC $21.4003/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207471682 CMS
W. L. Gore & Associates, Inc. $191.3303/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220974804 CMS
ABBVIE INC. $41.1402/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203826276 CMS
ABBVIE INC. $149.1602/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203826280 CMS
Glaukos Corporation $15.1502/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246395428 CMS
W. L. Gore & Associates, Inc. $24.7402/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220974802 CMS
W. L. Gore & Associates, Inc. $440.0002/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1220971473 CMS
Glaukos Corporation $15.8901/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246395547 CMS
Bausch & Lomb Americas Inc. $15.3801/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254785389 CMS
Glaukos Corporation $21.9001/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246395541 CMS
Glaukos Corporation $3.8301/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246395543 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,018.19 52
PY2020 $8,794.18 30
PY2021 $10,266.72 21
PY2022 $11,786.62 38
PY2023 $2,150.61 19
PY2024 $12,811.17 34
PY2025 $12,665.72 64

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $70.00 1
PY2025 Principal investigator $199,939.36 61
PY2024 Principal investigator $75,257.13 31
PY2023 Principal investigator $53,196.48 32
PY2022 Principal investigator $106,368.03 45
PY2021 Principal investigator $255,613.29 45
PY2020 Recipient $2,367.32 2
PY2020 Principal investigator $244,885.86 48
PY2019 Principal investigator $254,624.54 58

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Glaukos Corporation $3,820.00 12/10/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911432
Principal investigator 1 Glaukos Corporation $1,587.97 12/10/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250911446
Principal investigator 1 ABBVIE INC. $697.50 12/04/2025 Non-covered Recipient Entity
ARIZONA ADVANCED EYE RESEARCH
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202527708
Principal investigator 1 Glaukos Corporation $6,600.00 11/26/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
Prospective, Multicenter Study of PRESERFLOMicroShunt in Subjects with Primary Open-AngleGlaucoma Who Have Failed Previous Medical and SurgicalTreatment No dispute reported 06/30/2026 1250910449
Principal investigator 1 Glaukos Corporation $150.00 11/26/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910625
Principal investigator 1 Glaukos Corporation $1,530.00 11/19/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911430
Principal investigator 1 Glaukos Corporation $6,810.00 11/19/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250911444
Principal investigator 1 Glaukos Corporation $1,430.00 11/19/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911488
Principal investigator 1 ABBVIE INC. $3,085.00 11/05/2025 Non-covered Recipient Entity
ARIZONA ADVANCED EYE RESEARCH
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202522895
Principal investigator 1 Glaukos Corporation $1,350.00 10/22/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
Prospective, Multicenter Study of PRESERFLOMicroShunt in Subjects with Primary Open-AngleGlaucoma Who Have Failed Previous Medical and SurgicalTreatment No dispute reported 06/30/2026 1250910441
Principal investigator 1 Glaukos Corporation $475.00 10/22/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910471
Principal investigator 1 ABBVIE INC. $5,177.50 10/09/2025 Non-covered Recipient Entity
ARIZONA ADVANCED EYE RESEARCH
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202513881
Principal investigator 1 Glaukos Corporation $2,970.00 10/08/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911428
Principal investigator 1 Glaukos Corporation $9,405.00 10/08/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250911440
Principal investigator 1 Glaukos Corporation $1,090.00 10/08/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250911442
Principal investigator 1 Glaukos Corporation $7,850.00 10/08/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911486
Principal investigator 1 Glaukos Corporation $300.00 10/01/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910489
Principal investigator 1 Glaukos Corporation $393.75 09/10/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
Prospective, Multicenter Study of PRESERFLOMicroShunt in Subjects with Primary Open-AngleGlaucoma Who Have Failed Previous Medical and SurgicalTreatment No dispute reported 06/30/2026 1250910649
Principal investigator 1 Glaukos Corporation $3,480.00 09/10/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911426
Principal investigator 1 Glaukos Corporation $1,475.00 09/10/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911484
Principal investigator 1 ABBVIE INC. $10,425.00 09/04/2025 Non-covered Recipient Entity
ARIZONA ADVANCED EYE RESEARCH
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202508594
Principal investigator 1 Glaukos Corporation $394.74 08/27/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903907
Principal investigator 1 Glaukos Corporation $14.52 08/13/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250902515
Principal investigator 1 Glaukos Corporation $59.12 08/13/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250902689
Principal investigator 1 ABBVIE INC. $4,723.75 08/06/2025 Non-covered Recipient Entity
ARIZONA ADVANCED EYE RESEARCH
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202502626
Principal investigator 1 Glaukos Corporation $2,715.00 08/06/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911424
Principal investigator 1 Glaukos Corporation $525.00 08/06/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911482
Principal investigator 1 Glaukos Corporation $394.74 07/23/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903766
Principal investigator 1 ABBVIE INC. $5,080.00 07/02/2025 Non-covered Recipient Entity
ARIZONA ADVANCED EYE RESEARCH
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202494203
Principal investigator 1 Glaukos Corporation $3,005.00 07/02/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911422
Principal investigator 1 Glaukos Corporation $9,655.00 07/02/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250911438
Principal investigator 1 Glaukos Corporation $815.00 07/02/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911480
Principal investigator 1 Glaukos Corporation $17.72 06/18/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903061
Principal investigator 1 Glaukos Corporation $15.88 06/11/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903127
Principal investigator 1 Glaukos Corporation $517.24 06/04/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904033
Principal investigator 1 Glaukos Corporation $1,600.00 06/04/2025 Covered Recipient Teaching Hospital
Uh Cleveland Medical Center
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250910665
Principal investigator 1 Glaukos Corporation $3,115.00 06/04/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911420
Principal investigator 1 Glaukos Corporation $3,995.00 06/04/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911478
Principal investigator 1 Glaukos Corporation $197.37 05/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904150
Principal investigator 1 Glaukos Corporation $197.37 05/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904292
Principal investigator 1 Glaukos Corporation $114.84 05/14/2025 Non-covered Recipient Entity
OCPC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250903328
Principal investigator 1 Glaukos Corporation $394.74 05/14/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250904708
Principal investigator 1 Glaukos Corporation $965.00 05/07/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911418
Principal investigator 1 Glaukos Corporation $1,500.00 05/07/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250911436
Principal investigator 1 Glaukos Corporation $8,225.00 05/07/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911476
Principal investigator 1 ABBVIE INC. $10,093.00 04/03/2025 Non-covered Recipient Entity
ARIZONA ADVANCED EYE RESEARCH
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202471655
Principal investigator 1 Glaukos Corporation $517.24 04/02/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904580
Principal investigator 1 Glaukos Corporation $3,030.00 04/02/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911416
Principal investigator 1 Glaukos Corporation $258.62 03/12/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904471
Principal investigator 1 Glaukos Corporation $4.67 03/05/2025 Non-covered Recipient Entity
Amazon.com, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250909557
Principal investigator 1 Glaukos Corporation $150.18 03/05/2025 Non-covered Recipient Entity
Fracture Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911347
Principal investigator 1 Glaukos Corporation $19,860.00 03/05/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911414
Principal investigator 1 Glaukos Corporation $2,000.00 03/05/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250911474
Recipient ABBVIE INC. $70.00 02/28/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma No dispute reported 06/30/2026 1202400715
Principal investigator 1 Glaukos Corporation $394.74 02/26/2025 Non-covered Recipient Entity
Greenphire, Inc.
A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA No dispute reported 06/30/2026 1250905106
Principal investigator 1 Glaukos Corporation $258.62 02/19/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904961
Principal investigator 1 Glaukos Corporation $421.30 02/19/2025 Non-covered Recipient Entity
Commercial Print Management
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone No dispute reported 06/30/2026 1250907880
Principal investigator 1 Glaukos Corporation $3,500.00 02/12/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911412
Principal investigator 1 Glaukos Corporation $258.62 01/29/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250904848
Principal investigator 1 Glaukos Corporation $258.62 01/08/2025 Non-covered Recipient Entity
Greenphire, Inc.
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250905536
Principal investigator 1 Glaukos Corporation $37,950.00 01/08/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension No dispute reported 06/30/2026 1250911410
Principal investigator 1 Glaukos Corporation $2,645.00 01/08/2025 Non-covered Recipient Entity
Arizona Advanced Eye Research Institute LLC
Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% No dispute reported 06/30/2026 1250911434